1 Evaluate the risk in conventional IVF frozen human blastocysts undergoing PGT using a
2 new quantification method for parental contamination testing (qPCT)

3 Authords: Yunqiao Dong, Ph.D.,^a Dun Liu, Ph.D.,^a Yangyun Zou Ph.D.,^b Cheng Wan Ph.D.,^b
 4 Chuangqi Chen, M.S.,^a Mei Dong M.D.,^a Ph.D.,^a Yuqiang Huang M.S.,^a Cuiyu Huang M.S.,^a
 5 Huinan Weng M.D.,^a Ph.D.,^a Xiulan Zhu M.D.,^a Ph.D.,^a, Fang Wang M.D.,^a Ph.D.,^a Shujing Jiao
 6 M.S.,^b Na Liu M.S.,^b Sijia Lu Ph.D.,^b Xiqian Zhang, M.D.,^a Ph.D.,^a Fenghua Liu, M.D.^a

7 Affiliations:

8 ^a Reproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou Medical
 9 University, Guangzhou, 511400, Guangdong Province, China; ^b Yikon Genomics Company, Ltd.,
 10 Shanghai 201499, China

11 Y.D., D.L., Y.Z. and C.W. should be considered similar in author order.

12 Corresponding Author: Fenghua Liu,

13 No.521 Xingnan Rd.,Guangzhou 511400,Guangdong Province, China.

14 Tel:86-20-39151861

15 E-mail: liushine2006@163.com

16 Capsule:

17 During PGT for human frozen conventional IVF embryos, paternal source pollution is negligible,
 18 while maternal pollution can not be ignored. qPCT method can effectively detect the parent DNA
 19 contamination in WGA products of biopsied TE cells.

20

21 **Abstract:**

22 **Objective:** To establish a method to assess risks associated with preimplantation genetic testing
23 (PGT) in embryos simultaneously with adhered sperm and cumulus cells.

24 **Design:** A prospective pilot study.

25 **Setting:** University teaching hospital.

26 **Patient(s):** 120 frozen blastocysts that could be biopsied from 34 patients who had experienced
27 repeated implantation failure or abortion due to chromosomal abnormalities after embryos transfer
28 in prior routine IVF cycles.

29 **Intervention(s):** Chromosome screening and parental DNA contamination testing was performed
30 in the surplus frozen IVF blastocysts from 34 patients.

31 **Main Outcome Measure(s):** Parental DNA contamination rate and euploidy rate in biopsied
32 blastocysts.

33 **Result(s):** A new quantification method for parental contamination testing (qPCT) in single-cell
34 whole-genome amplification (WGA) products based on allelic ratio analysis was established and
35 validated in an artificial model by comparing 22 results obtained before and after adding different
36 numbers of sperm and cumulus cells to biopsied TE cells. The results of the prospective clinical
37 study of qPCT-PGT-A showed that the maternal contamination rate was 0.83% (1/120) and the
38 risk of paternal contamination was negligible. The euploidy rate in these blastocysts was 47.50%
39 (57/120), and 21 frozen embryo transfer (FET) cycles resulted in ten ongoing clinical pregnancies
40 and four healthy births.

41 **Conclusion(s):** The evidence we provide in the study shows a low risk of PGT in embryos
42 simultaneously with adhered sperm and cumulus cells. The qPCT assay can be used to detect the
43 risk of potential contamination and ensure the accuracy of PGT results, thereby improving the
44 clinical outcome of IVF.

45 **Key Words:** Quantitative parental contamination testing, IVF, PGT, biopsy, human blastocyst

46

47 Introduction

48 For preimplantation genetic testing (PGT) to be clinically applicable, intracytoplasmic sperm
49 injection (ICSI) is usually required, rather than conventional in vitro fertilization (IVF)
50 insemination method, owing to potential parental contamination from sperm and cumulus cells
51 attached to the zona pellucida during conventional IVF (1-6). However, in many available studies
52 addressing non-male factor infertility, ICSI has not been proven to be beneficial for clinical
53 outcomes, and the risk of chromosomal defects is increased in ICSI offspring (7-12). Since sperm
54 DNA fails to amplify under the conditions used for trophectoderm (TE) biopsy samples, and
55 cumulus cells will be deliberately removed clearly in fresh IVF-PGT-A, the use of conventional
56 IVF has been preliminarily explored in fresh genetic testing for aneuploidies (PGT-A) cycles in
57 recent years (13-15). However, if without an intention to perform PGT in the beginning, there are
58 many sperm and cumulus cells exist simultaneously in the zona pellucida of conventional IVF
59 frozen blastocysts. Little is known about the maternal contamination risk of PGT in these embryos
60 and whether it adversely affects the accuracy of results in conventional IVF-PGT. Recently, a
61 study shows that 12.5% maternal DNA contamination was observed in blastocyst media,
62 indicating that potential maternal contamination should not be neglected (16).

63 Currently, the clinical need for PGT-A in frozen conventional IVF embryos is urgent. For
64 patients who have experienced repeated implantation failure or abortion due to chromosomal
65 abnormalities in previous embryo transfer cycles, the biopsy of the existing frozen embryos is not
66 only necessary but also cost-effective. However, there are many cumulus cells and sperm in the
67 zona pellucida especially from conventional IVF embryos, especially when there is no PGT
68 expectation in advance. With current methods, parental contamination in biopsy cells cannot be
69 detected accurately. Therefore, we verified whether PGT-A is feasible for embryos with potential
70 parental contamination.

71 To address this issue, we developed a parental contamination detection method for biopsy cells
72 which could exclude contaminated embryos and ensure the accuracy of PGT results. Thus far,
73 several approaches using single nucleotide polymorphism (SNP) genotyping information or short
74 tandem repeat (STR) markers to trace maternal genetic materials from fetal or miscarriage
75 specimens have been reported (17-19). However, such approaches require sufficient DNA for
76 genetic testing. Esteki and his collaborators proposed a concurrent whole-genome haplotyping

approach referred to as haplarithmis to resolve the parental origin of copy number variations (CNVs) in single cells, but the method is easily affected by low-quality amplification effects, such as high allele dropout (ADO) (20). To the best of our knowledge, no previous studies have reported parental contamination detection in single-cell whole-genome amplification (WGA) products from TE biopsied cells.

In this study, we first developed a new quantification method for parental contamination testing (referred to as qPCT) based on allelic ratios obtained from SNP genotypes that fully considers amplification bias, including preferential amplification or ADO effects. The qPCT assay was validated by comparing results before and after the artificial addition of sperm and cumulus cells to TE cells from discarded aneuploidy blastocysts. We then recruited 120 frozen embryos from 34 couples, with advanced age, experienced repeated implantation failure or abortion due to chromosome abnormalities, who had surplus frozen embryos from previous conventional IVF cycles available for biopsy. By using next-generation sequencing (NGS) with our qPCT method, we selected euploidy embryos with no parental contamination for transfer, resulting in four healthy live birth and ten ongoing clinical pregnancies. The method has the potential for application in much wider chromosome screening in clinical IVF due to increasing clinical needs and the limitations of the existing methods.

Materials and Methods

Preparation of embryos for the study. To establish the qPCT method, 30 reference samples, which are WGA products with normal PGT-A results and no parental contamination were collected, and to perform the simulated contamination test, six discarded aneuploidy embryos were collected. We conducted a prospective clinical study with patients recruited from January 2020 to April 2021. A total of 34 couples with indications for PGT-A due to advanced maternal age, repeated implantation failures or recurrent abortion who had surplus blastocysts from prior conventional IVF available for biopsy were recruited regardless of their prognosis, age, or diagnosis. The couples had no karyotype abnormalities. Approval for this study was obtained from the Ethics Committee of Guangdong Women and Children Hospital (Research Ethics Committee No. 202101109). All these samples were from Reproductive Medical Center of Guangdong Women and Children Hospital and all of the patients signed the informed consent form before any

107 study-specific procedures were performed. The whole protocol described below is summarized in
108 Figure. 3A. The clinical details of 34 couples are summarized in Table 2.

109 **Artificial addition of sperm and cumulus cells to TE cells.** To establish an artificial model for
110 detecting parental cells contamination in biopsied TE cells, frozen-thawed sperm and cumulus cell
111 was isolated, aspirated and put into the pipette with biopsy cells. To simulate the freezing process
112 of sperm on the zona pellucida, the method involving the zona pellucida combined with sperm
113 was used (Supplementary, Figure. S1).

114 **Blastocyst biopsy.** Frozen stage 5 or 6 blastocysts were thawed in advance and cultured 2-4 h
115 prior to biopsy, whereas frozen day 3 embryos were thawed 2–3 days in advance. Every blastocyst
116 that reached the blastocyst stage and fulfilled the biopsy criteria was biopsied. Biopsy was
117 performed in 10- μ l drops of G-MOPS-PLUS, the blastocyst was fixed and positioned with a clear
118 view of the inner cell mass (ICM) at 9-12 o'clock, and the hatched TE cells were aspirated into the
119 biopsy pipette, followed by three laser pulses of 2.0 ms (ZYLOS-tk[®], Hamilton Thorne, MA, USA)
120 to loosen cell connections and the application of the mechanical 'flicking' method to cut away the
121 TE cells using the biopsy pipette and holding pipette. When a blastocyst was not hatched, the zona
122 pellucida was perforated by a laser for 2.0 ms, after which the collapse of the blastocyst was
123 induced before biopsy. TE cells were washed and placed in 0.2-ml PCR tubes with 1–2.0 μ l PBS
124 and stored at –20°C until further processing. Approximately 10 biopsy cells from one discarded
125 aneuploidy blastocyst were artificially mixed with sperm or cumulus cells and 4–6 TE cells were
126 biopsied for clinical application of qPCT-PGT. All embryos were cryopreserved by vitrification
127 (Life Global[®], USA) within 1 h after biopsy and stored at -196°C.

128 **Whole-genome amplification of sperm, cumulus and TE cells.** Single-cell WGA were
129 performed in 22 samples of sperm cells (20 cells per sample) and three samples of cumulus cells
130 (one cell per sample) under different conditions used for TE biopsy samples (Figure. 1A and 1B).
131 The multiple annealing and loop-based amplification cycles (MALBAC)-based single-cell WGA
132 kit (ChromSwiftTM, Cat. No. KT110700324, Yikon Genomics Ltd, Suzhou, China), the
133 PicoPLEX single-cell WGA kit (Rubicon Genomics, Ann Arbor, USA) and the multiple
134 displacement amplification (MDA)-based single-cell WGA Kit (Cat. No. 150343, Qiagen, USA)
135 were utilized to amplify DNA from different types of cells according to the manufacturer's
136 instructions.

Determination of blastocyst ploidy status by NGS. To analyze the ploidy status of blastocysts, the amplified DNA of TE samples was sequenced using a NextSeq 550 sequencer (Cat No. SY-415-1002, Illumina, Inc., USA) with a single-ended read length of 55 bp. Approximately 2 million raw reads were generated for each TE sample. Genome-wide CNVs were analyzed to determine the euploidy or aneuploidy status of each embryo. Aneuploid embryos were diagnosed when the size of CNVs was greater than 4 Mb and the extent of mosaicism was above 30%.

Genotyping assay of blastocysts and parental genomes. To determine the genotype of each blastocyst and parental genome, the Infinium Asian Screening Array (ASA) bead chip (Cat No. 20016317, Illumina, Inc., USA) and the iScan system (Cat No. SY-101-1001, Illumina, Inc., USA) were utilized. Parental genomic DNA was extracted from the peripheral blood of the parents of each blastocyst. Genomic DNA, along with the amplified DNA of TE samples, was linearly amplified, fragmented, precipitated and hybridized according to the manufacturer's instructions. Signal scanning was performed with the iScan system. Iaap-cli gencall algorithm (Version 1.1.0, Illumina, Inc., USA) was applied to analyze the genotype of each sample, and the BAF and log R ratio (LRR) values of all SNPs were generated simultaneously.

Determination of parental contamination by BAF analysis. As shown in (Figure. 1F), theoretically, the BAFs of genotypes AA, AB and BB should be approximately 0, 0.5 and 1, respectively. For a SNP with paternal AA and maternal BB genotypes or paternal BB and maternal AA genotypes, the genotype of the embryo is genetically expected to be heterozygous AB, with a BAF of approximately 0.5. Deviation from a BAF of 0.5 for the embryo may be caused by parental contamination, DNA copy number aberrations or allelic amplification bias and errors (e.g. allele dropout or preferential amplification of one allele) resulting from single-cell WGA technology. Selecting SNP j with homozygous genotypes but different alleles between the father and mother, maternally and paternally biased SNPs in an embryo were defined according to a $BAF \geq 0.6$ (S_M , SNP site for maternal bias) and $BAF \leq 0.4$ (S_P , SNP site for paternal bias) given maternal and paternal genotypes of BB and AA, respectively; for maternal and paternal genotypes of AA and BB, maternally and paternally biased SNPs were determined according to a $BAF \leq 0.4$ (S_M) and $BAF \geq 0.6$ (S_P) (Figure. 1F). Relative parental origin bias (POB) statistics were thus constructed and formulated for each chromosome, i , as follows:

$$R_{POB_i} = \frac{\sum_j S_{M_{i,j}}}{\sum_j S_{P_{i,j}}}$$

167

168 Based on reference samples from euploid embryos without parental contamination, a positively
169 skewed normal distribution of R_{POB_i} with a mean value of 1.14 was obtained (Figure. S1B).

170 Here, a tested sample with an R_{POB_i} value significantly greater than 1.14 is indicated to show

171 maternal origin bias, implying maternal contamination (most chromosomes with numbers ≥ 15

172 share the same pattern), or chromosome-level maternal-origin DNA replication, or uniparental

173 disomy, or paternal-origin DNA deletion with a P -value < 0.05 (Mean+3*SD); on the contrary, a

174 tested sample with an R_{POB_i} value significantly less than 1.14 is indicated to show

175 paternal-origin bias, with the possibility of paternal contamination (most chromosomes with

176 numbers ≥ 15 share the same pattern), or chromosome-level paternal-origin DNA replication, or

177 uniparental disomy, or maternal-origin DNA deletion with a P -value < 0.05 (Mean-2*SD, standard

178 deviation). R_{POB} statistics can to some degree eliminate allelic amplification bias from WGA.

179 **Preparation and analyzing of artificially contaminated gDNA.** To address the issue of

180 quantification of parental contamination, we establish a standard curve, which represents the

181 correlation between the POB value and the ratio of parental contamination. Parents genomic DNA

182 was extracted from peripheral blood samples, while fetal genomic DNA was extracted from tissue

183 of spontaneous abortion. A commercial genomic DNA extraction kit (DNeasy Blood & Tissue Kit,

184 Cat. No. 69504, Qiagen, USA) was used according to the manufacturer's instructions. Paternal/fet

185 al and maternal/fet al DNA was mixed in different proportion (Figure. 1G). The artificially

186 contaminated DNA was then diluted to 50pg/ μ L, and amplified by using a ChromInst Single cell

187 WGA kit (Cat. No. Yikon Genomics Ltd, Suzhou, China) according to the manufacturer's

188 instructions. Finally, the amplified DNA was analyzed by using the Infinium Asian Screening

189 Array (ASA) bead chip (Cat No. 20016317, Illumina, Inc. USA) and the iScan system (Cat No.

190 SY-101-1001, Illumina, Inc. USA) to obtain the BAF value of each SNP loci. The R_{POB} was

191 calculated to establish the standard curve of the ratio of parental contamination.

192 **Measurement of clinical outcomes.** Biochemical was defined as β -HCG > 5 U/L detected 12

193 days after blastocyst transfer, but no gestational sac was found by transvaginal ultrasound.
194 Negative was defined as β -HCG <5 U/L detected 12 days after blastocyst transfer. Clinical
195 pregnancy was defined by fetal cardiac activity. Non-invasive prenatal testing (NIPT) was
196 performed at 12–18 weeks of gestation.

197

198 **Results**

199 **WGA of sperm and cumulus cells.** We performed WGA and copy number variation sequencing
200 (CNV-seq) in 22 samples of frozen-thawed sperm cells and three samples of frozen-thawed
201 cumulus cells (Figure 1A and 1B). As shown in Figure. 1C, no DNA smears were observed in the
202 MALBAC-WGA and Picoplex-WGA products of the sperm samples, while positive results were
203 obtained from the MDA-WGA products. However, cumulus cell DNA can be easily amplified by
204 the three methods (Figure 1D). The MALBAC-CNV-seq and Picoplex-CNV-seq of sperm
205 samples also failed to generate qualified results, showing low genome coverage of 0.31% to
206 1.08% and relatively high coefficients of variation (CV) ranging from 23% to 50% (Figure 1E).
207 However, three cumulus cell samples presented high-quality CNV-seq results, showing normal
208 karyotypes of the three samples (Figure 1D and 1E). These results are partially in accordance with
209 previous studies (15), indicating the difficulty of amplifying sperm DNA.

210 **Establishment of qPCT.** To establish the qPCT method, we first collected 30 reference samples
211 from euploid embryos without parental contamination, which were defined as embryos with
212 normal ploidy and XY chromosomes. The POB values of these reference samples were calculated
213 based on the B allele frequency (BAF) of selected SNP loci (Figure. 1F and Supplementary Figure.
214 S2) approximately followed a positively skewed normal distribution, with a mean (Mean) of 1.14
215 and standard deviation (SD) of 0.30. Therefore, the POB range for non-contaminating euploid
216 embryos was defined as 0.54 to 2.04 (Mean $-2 \times$ SD to Mean $+ 3 \times$ SD), and a qualitative standard of
217 parental contamination was established.

218 To further address the issue of the quantification of parental contamination, gDNA of tissue
219 samples from spontaneous abortions and blood samples from parents was mixed in specific
220 proportions. The mixed gDNA was diluted to an approximate concentration of 50 pg/ μ L and then
221 amplified, sequenced and analyzed in accordance with the PGT-A procedure. Genotyping assays
222 were also performed. As a result, the POB values of the artificially added contaminant fet al

gDNA showed a positive correlation with the proportion of mixed parental gDNA (Figure 1G and 1H). The relative quantification of parental contamination could be performed by using the standard curve.

Detection of contamination in artificially contaminated TE samples. To verify the accuracy and repeatability of qPCT in detecting parental contamination in biopsy cells, we added gDNA from the peripheral blood of parents to the WGA products and found that the detection rate was 100% (10/10) (Supplementary Figure S3). However, no significant contamination was detected in artificially contaminated TE samples containing approximately 10 biopsy cells and 1 cumulus cell (Table 1).

To reveal the correlation between the PGT-A results and parental contamination, we selected discarded aneuploid blastocysts, added different numbers of sperm cells or cumulus cells to biopsied TE samples, and performed PGT-A and qPCT in these samples. The results showed that no paternal contamination was detected, and no change in the PGT-A results was observed, regardless of the number of added sperm cells (Figure 2A and Table 1). On the other hand, the proportion of maternal contamination increased gradually with the increase in the number of added cumulus cells, and a notable correlation was observed (Figure 2B and Table 1).

Prospective clinical study of qPCT-PGT-A in thawed IVF blastocysts. After the systematic validation of the qPCT assay, we performed qPCT-PGT-A in a total of 120 frozen blastocysts from 34 recruited patients as described in the materials. The procedure of qPCT-combined PGT-A is shown in (Figure. 3A) The qPCT results revealed a maternal contamination rate of 0.83% (1/120, case qpcts8), and no paternal contamination was detected, as expected (Table 2 and Figure 3B). Notably, one sample from case qpcts26 was defined as aneuploid with suspicious paternal contamination (Table 2 and Supplementary Figure S4A). To confirm this, the sample was collected and lysed for heteroploid detection using the whole embryo, and a paternal origin of triploid result was revealed (Table 2 and Supplementary, Figure S4B). The PGT-A results showed that the euploidy rate of these frozen blastocysts was 47.50% (57/120), and at least one euploid blastocyst was obtained for frozen embryo transfer (FET) in 28 of these patients (Table 2). Single-blastocyst transfer was performed in twenty-one patients, resulting in four healthy birth and ten ongoing clinical pregnancies (Table 2). To date, no early abortion has occurred, and we continue to follow up the last ongoing pregnancy. The detailed clinical indications and outcomes

are summarized in Table 2.

Discussion

WGA of sperm cells and the effect on PGT-A. Sperm are the main source of paternal contamination, and sperm attached to the zona pellucida cannot be removed in fresh or frozen embryos from conventional IVF cycles. Several studies have shown that sperm DNA is difficult to be amplified by using routine protocols for TE biopsy samples (15, 21), but little evidence indicating the risk and ratio of paternal contamination in conventional IVF PGT-A has been reported. In this study, a comprehensive investigation of paternal contamination was performed with a 3-step study design. First, we performed MALBAC-WGA of isolated sperm cells, and the results of both agarose gel electrophoresis and CNV-seq showed amplification failure, even if 20 sperm cells were tubed (Figure 1C). Although the immobilized motile sperm were subjected to freeze-thawing, the sperm remained intact and did not show signs of degeneration. Also, a similar negative result was found by Neelke et al using PicoPlex WGA (15). In contrast, sperm DNA could be amplified by using MDA (Figure 1C and 1E), indicating a higher risk of paternal contamination in the application of MDA-based PGT in IVF embryos. Second, we performed PGT-A and qPCT with artificially mixed TE and sperm cells, resulting in no change in the PGT-A results and no paternal contamination. Finally, we conducted a prospective clinical study with 120 frozen conventional IVF blastocysts; unsurprisingly, no paternal contamination was detected (Table 2). This evidence indicates that the risk of paternal contamination is negligible and that PGT can be applied in patients undergoing conventional IVF with the MALBAC system. As mentioned above, it is difficult to eliminate the possibility that sperm cells could spontaneously disruption in the real world or use other WGA systems.

Maternal contamination from cumulus cells and the effect on PGT-A. Cumulus cells are the main source of maternal genetic contamination in TE samples. Unlike sperm, cumulus cell DNA can be easily amplified during the PGT procedure. A notable correlation between the number of cumulus cells and the proportion of maternal contamination was observed by using the qPCT method (Table 1). The results suggested that severe maternal contamination would lead to false-negative results, and partial maternal contamination would cause to mosaicism. Therefore, to identify false-negative results caused by maternal contamination, it is necessary to apply

contamination quantification methods, such as qPCT, in the PGT-A of both ICSI and conventional IVF embryos.

Advantages and limitations of the qPCT method. In the PGT scenario, biopsy specimens from blastocysts usually require single-cell whole genome amplification to provide sufficient DNA for genetic testing. However, ADO (PCR failure for one allele) and/or preferential amplification (hypoamplification of one allele) resulting from WGA technology cause SNP genotyping to be unreliable (20). Therefore, many proposed parental cell contamination testing methods involving gDNA samples from tissue without WGA cannot be employed in PGT applications (17-19). For this reason, we developed a parental orientation test based on the allelic ratio determined via B allele frequency (BAF) analysis to address the parental contamination issue in IVF-PGT-A. Our method fully considers amplification biases, such as preferential amplification or ADO, which are relatively insensitive to single-cell WGA quality. Meanwhile, combined with WGA specific BAF pattern resolution, parental contamination or heteroploidy may be further discriminative (Supplementary Figure S4). Technically, any WGA method is applicable for qPCT. Also, preimplantation genetic testing for monogenic (PGT-M) as well as preimplantation genetic testing for chromosomal structural rearrangements (PGT-SR) are theoretically feasible for conventional IVF insemination method by using qPCT. The method does not require specialized equipment or complex experimental procedures; therefore, it can be fully adapted for routine use in a molecular diagnostic laboratory. However, this approach requires parental genetic information for combined analysis, thus limiting its large-scale clinical application to some degree. Moreover, a method of parental contamination removal is urgently needed to provide accurate PGT results for biopsy samples, even samples contaminated by parental genetic material. Epigenetic signal discrimination between embryonic and parental cell DNA may be a promising way to trace the cellular origin of DNA samples, which might filter out the effect of parental contamination in the future (22).

The need for qPCT clinical application in frozen blastocysts. The biopsy of the existing frozen IVF blastocysts to meet patients' clinical needs not only increases embryo utilization but also reduces physical and economic burdens. Thus, IVF physicians and embryologists must understand and select the programs available to them. The only barrier to this strategy is that the potential risk of parental DNA contamination cannot be excluded. Unlike ICSI-PGT-A or fresh IVF-PGT-A

(17-19), cumulus cells are not required to completely removed in conventional IVF when there is no PGT expectation in advance (Figure 3C). As a result, it is difficult to always avoid sperm and/or cumulus cells attached to the spherical zona pellucida during TE cells biopsy (Figure 3D). Moreover, the DNA of sperm or granular cells disrupted by a laser might disperse into the biopsy fluid during biopsy. Therefore, it is necessary to detect parental contamination in biopsy cells under such conditions. Frozen IVF blastocyst biopsy samples will be resuscitated in advance, so the blastocyst TE cells will hatch from the holes generated by freezing and draining water or artificial openings made after thawing. In this study, 71.67% of blastocysts were stage 5 and 6 blastocysts with TE cells located far away from the zona pellucida (Supplementary Table 1), which could partly explain the reason for the low contamination detection rate in this study. Admittedly, the major disadvantages of the applied clinical strategy are that (□) it requires invasive embryo biopsy and (□) repeated cryopreservation of embryos is usually unavoidable. There are still safety concerns with these procedures (23-28). In the future, rapid noninvasive chromosome screening or mutation identification combined with qPCT will be a promising research area (29-33). However, as the clinical strategy yielded a clinical pregnancy rate of 57.14% without adverse outcomes, patients with existing frozen conventional IVF embryos could be counseled regarding this new option.

In summary, the risk of PGT in embryos with potential parental contamination is relatively low. We have established a practical and easy-to-implement clinical strategy, qPCT, for detecting potential parental contamination from sperm and cumulus cells especially in frozen conventional IVF embryos and ensuring the accuracy of PGT results. Our validation data and initial clinical applications strongly suggest that the qPCT-PGT assay can help to improve clinical outcomes via the chromosome screening of frozen conventional IVF embryos in a manner allowing their reuse. We envision that multicenter randomized clinical trials will be designed and performed in the future, which will further evaluate the clinical safety and effectiveness of the qPCT-PGT assay.

337
338

339 **Acknowledgements**

340 We thank the patients for their participation in this study. This work was supported by grants from
341 the Science and Technology Program of Guangzhou (201704020217), the National Key Research
342 and Development Program of China (2018YFC1002604) and the National Natural Science
343 Foundation of China (81800184).

344

345 **Author Contributions:**

346 Y.D., D.L., C.W., Y.Z., S.L., X.Z., F.L. designed research; Y.D., D.L., C.C., M.D., Y.H., C.H.,
347 H.W., X.Z., F.W., X.Z., N.L. performed research; Y.D., D.L., C.W., Y.Z., S.J., S.L., F.L. analyzed
348 data; Y.D., D.L., C.W., Y.Z. wrote the paper.

349

350

351

352

353 **References**

- 354 1.Thornhill AR, deDie-Smulders CE, Geraedts JP, Harper JC, Harton GL, Lavery SA, etal.
- 355 ESHRE PGD Consortium. ESHRE PGD Consortium 'Best practice guidelines for clinical
- 356 preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)'. Hum
- 357 Reprod 2005;20:35-48.
- 358 2. ESHRE Capri Workshop Group. Intracytoplasmic sperm injection (ICSI) in 2006: evidence and
- 359 evolution. Hum Reprod Update 2007;13:515-526.
- 360 3.Harton GL, Magli MC, Lundin K, Montag M, Lemmen J, Harper JC; European Society for
- 361 Human Reproduction and Embryology (ESHRE) PGD Consortium/Embryology Special Interest
- 362 Group. ESHRE PGD Consortium/Embryology Special Interest Group--best practice guidelines for
- 363 polar body and embryo biopsy for preimplantation genetic diagnosis/screening (PGD/PGS). Hum
- 364 Reprod 2011;26:41-46.
- 365 4.Berger VK, Baker VL. Preimplantation diagnosis for single gene disorders. Semin Reprod Med
- 366 2014;32:107-113.
- 367 5.Kokkali G, Coticchio G, Bronet F, Celebi C, Cimadomo D, Goossens V, etal. ESHRE PGT
- 368 Consortium and SIG Embryology good practice recommendations for polar body and embryo
- 369 biopsy for PGT. Hum Reprod Open 2020;2020:hoaa020.
- 370 6.Coonen E, Rubio C, Christopikou D, Dimitriadou E, Gontar J, Goossens V, etal. ESHRE PGT
- 371 Consortium good practice recommendations for the detection of structural and numerical
- 372 chromosomal aberrations. Hum Reprod Open 2020;2020:hoaa017.
- 373 7.Ming L, Yuan C, Ping Z, Ping L, Jie Q. Conventional in vitro fertilization maybe yields more
- 374 available embryos than intracytoplasmic sperm injection for patients with no indications for ICSI.
- 375 Int J Clin Exp Med 2015;8:21593-21598.
- 376 8.Grimstad FW, Nangia AK, Luke B, Stern JE, Mak W. Use of ICSI in IVF cycles in women with
- 377 tubal ligation does not improve pregnancy or live birth rates. Hum Reprod 2016 ;31:2750-2755.
- 378 9.Tannus S, Son WY, Gilman A, Younes G, Shavit T, Dahan MH. The role of intracytoplasmic
- 379 sperm injection in non-male factor infertility in advanced maternal age. Hum Reprod
- 380 2017;32:119-124.
- 381 10.Sustar K, Rozen G, Agresta F, Polyakov A. Use of intracytoplasmic sperm injection (ICSI) in
- 382 normospermic men may result in lower clinical pregnancy and live birth rates. Aust N Z J Obstet

383 Gynaecol 2019;59:706-711.

384 11.Farhi J, Cohen K, Mizrahi Y, Weissman A, Raziel A, Orvieto R. Should ICSI be implemented
385 during IVF to all advanced-age patients with non-male factor subfertility? Reprod Biol Endocrinol
386 2019;17:30.

387 12.Luke B, Brown MB, Wantman E, Forestieri NE, Browne ML, Fisher SC, Yazdy MM, Ethen
388 MK, Canfield MA, Watkins S, et al. The risk of birth defects with conception by ART. Hum
389 Reprod 2021;36:116-129.

390 13.Feldman B, Aizer A, Brengauz M, Dotan K, Levron J, Schiff E, et al. Pre-implantation genetic
391 diagnosis-should we use ICSI for all? J Assist Reprod Genet 2017;34:1179-1183.

392 14.Niu X, Long J, Gong F, Wang W. Does ICSI for in vitro fertilization cause more aneuploid
393 embryos? Mol Cytogenet 2020;13:27.

394 15.Neelke De Munck N, El Khatib I, Abdala A, El-Damen A, Bayram A, Arnanz A, et al.
395 Intracytoplasmic sperm injection is not superior to conventional IVF in couples with non-male
396 factor infertility and preimplantation genetic testing for aneuploidies (PGT-A). Hum Reprod
397 2020;35:317-327.

398 16.Rubio C, Navarro-Sánchez L, García-Pascual CM, Ocali O, Cimadomo D, Venier W, et al.
399 Multicenter prospective study of concordance between embryonic cell-free DNA and
400 trophoctoderm biopsies from 1301 human blastocysts. Am J Obstet Gynecol 2020;223:751.

401 17.Liao GJ, Chan KC, Jiang P, Sun H, Leung TY, Chiu RW, et al. Noninvasive prenatal diagnosis
402 of fet al trisomy 21 by allelic ratio analysis using targeted massively parallel sequencing of
403 maternal plasma DNA. PLoS One 2012;7:e38154.

404 18.Lathi RB, Gustin SL, Keller J, Maisenbacher MK, Sigurjonsson S, Tao R, et al. Reliability of
405 46,XX results on miscarriage specimens: a review of 1,222 first-trimester miscarriage specimens.
406 Fertil Steril 2014;101:178-182.

407 19.Buchovecky CM , Nahum O, Levy B. Assessment of Maternal Cell Contamination in Prenatal
408 Samples by Quantitative Fluorescent PCR (QF-PCR). Methods Mol Biol 2019;1885:117-127.

409 20.Zamani Esteki M, Dimitriadou E, Mateiu L, Melotte C, Van der Aa N, Kumar P, et al.
410 Concurrent whole-genome haplotyping and copy-number profiling of single cells. Am J Hum
411 Genet 2015;96:894-912.

412 21.Patassini C, Garolla A, Bottacin A, Menegazzo M, Speltra E, Foresta C, et al. Molecular

413 karyotyping of human single sperm by array- comparative genomic hybridization. PLoS One
414 2013;8:e60922.

415 22.Chen Y, Gao Y, Jia J, Chang L, Liu P, Qiao J, et al. DNA methylome reveals cellular origin of
416 cell-free DNA in spent medium of human preimplantation embryos. J Clin Invest
417 2021;131:e146051.

418 23.Koch J, Costello MF, Chapman MG, Kilani S, Twice-frozen embryos are no detriment to
419 pregnancy success: a retrospective comparative study. Fertil Steril 2011;96:58-62.

420 24.Zhao HC, Zhao Y, Li M, Yan J, Li L, Li R, et al. Aberrant epigenetic modification in murine
421 brain tissues of offspring from preimplantation genetic diagnosis blastomere biopsies. Biol Reprod
422 2013;89:117.

423 25.Zeng Y, Lv Z, Gu L, Wang L, Zhou Z, Zhu H, et al. Preimplantation genetic diagnosis (PGD)
424 influences adrenal development and response to cold stress in resulting mice. Cell Tissue Res
425 2013;354:729-741.

426 26. Wu Y, Lv Z, Yang Y, Dong G, Yu Y, Cui Y, et al. Blastomere biopsy influences epigenetic
427 reprogramming during early embryo development, which impacts neural development and
428 function in resulting mice. Cell Mol Life Sci 2014;71:1761-1774.

429 27.Cimadomo D, Capalbo A, Ubaldi FM, Scarica C, Palagiano A, Canipari R, et al. The Impact of
430 Biopsy on Human Embryo Developmental Potential during Preimplantation Genetic Diagnosis.
431 Biomed Res Int 2016; 2016:7193075.

432 28.Zheng X, Chen Y, Yan J, Wu Y, Zhuang X, Lin S, et al. Effect of repeated cryopreservation on
433 human embryo developmental potential. Reprod Biomed Online 2017;35:627-632.

434 29. Fang R, Yang W, Zhao X, Xiong F, Guo C, Xiao J, et al. Chromosome screening using culture
435 medium of embryos fertilised in vitro: a pilot clinical study. J Transl Med 2019;17:73.

436 30.Jiao J, Shi B, Sagnelli M, Yang D, Yao Y, Li W, et al. Minimally invasive preimplantation
437 genetic testing using blastocyst culture medium. Hum Reprod 2019;34:1369-1379.

438 31. Huang L, Bogale B, Tang Y, Lu S, Xie XS, Racowsky C. Noninvasive preimplantation genetic
439 testing for aneuploidy in spent medium may be more reliable than trophectoderm biopsy. Proc
440 Natl Acad Sci U S A. 2019;116:14105-14112

441 32. Liu W, Liu J, Du H, Ling J, Sun X, Chen D. Non-invasive pre-implantation aneuploidy
442 screening and diagnosis of beta thalassemia IVSII654 mutation using spent embryo culture

443 medium. Ann Med 2017 ;49:319-328.

444 33. Xu J, Fang R, Chen L, Chen D, Xiao JP, Yang W, et al. Noninvasive chromosome screening of

445 human embryos by genome sequencing of embryo culture medium for in vitro fertilization. Proc

446 Natl Acad Sci U S A 2016;113:11907-11912

447

448

449 **Figure captions**

450 **Figure 1.** Concept validation and establishment of qPCT. **A and B:** Isolated sperm and cumulus
 451 cells. Bar = 10 μ m. **C and D:** Electrophoresis for WGA products of sperm and cumulus cells. **M:**
 452 100 bp DNA marker; **NC:** negative control; **C-MAL:** 20 sperm cells amplified by MALBAC;
 453 **C-Pico:** 20 sperm cells amplified by Picoplex; **C-MDA:** 20 sperm cells amplified by MDA.
 454 **D-MAL:** single cumulus cell amplified by MALBAC; **D-Pico:** single cumulus cell amplified by
 455 Picoplex; **D-MDA:** single cumulus cell amplified by MDA. **E:** CNV-seq results of WGA products
 456 amplified sperm and cumulus cells using MALBAC/Picoplex/MDA. Upper: sperm cells; lower:
 457 single cumulus cell; **NC:** negative control. **F:** Schematic of assignment of SNP sites for
 458 paternal/maternal bias. **S_M:** SNP site for maternal bias; **S_P:** SNP site for paternal bias. **G:** Standard
 459 curve of qPCT established by artificially mixed parental and fetal gDNA. **X-axis:** ratio of added
 460 maternal/paternal gDNA; **Y-axis:** POB value ($\log_{10}$); Red triangle: maternal contamination
 461 samples; Blue rhombus: paternal contamination samples. **H:** qPCT results for artificially
 462 contaminated gDNA samples. **X-axis:** chromosome ID; **Y-axis:** POB value; **M5:** 50% maternal
 463 contamination sample (maternal DNA : fetal DNA = 1:1); **N0:** no contamination sample; **P5:** 50%
 464 paternal contamination sample (paternal DNA : fetal DNA = 1:1).

465 **Figure 2.** Validation of qPCT in the artificial model. **A:** Sperm cells (3 to 8 cells) were artificially
 466 added to approximately 10 biopsy TE cells respectively. **B:** Cumulus cells (1 to 3 cells) were
 467 artificially added to approximately 10 biopsy TE cells respectively.

468 **Figure 3.** Clinical application of qPCT-combined PGT-A in human conventional IVF embryos. **A:**
 469 Workflow of qPCT-combined PGT-A. **B:** Clinical sample with positive results of qPCT. Case ID
 470 qpcts8: maternal contamination. **C:** Three clinical application scenarios of PGT. Fresh ICSI-PGT:
 471 PGT in fresh blastocysts from ICSI cycles. Fresh IVF-PGT: PGT in fresh blastocysts from
 472 conventional IVF cycles. Frozen IVF-PGT: PGT in frozen-thaw blastocysts from conventional
 473 IVF cycles. **D:** Typical IVF embryos undergoing TE cells biopsy. Bar = 10 μ m.

474

475

476 **Table 1 Validation results of the qPCT method in the artificial model.**

Type of artificial contamination	Discarded aneuploid embryo	Karyotype	No. of added sperm cell or cumulus cell	Results of PGT-A	Results of parental contamination	Ratio of parental contamination*
Paternal	1	46,XY,+15(×3),-22(×1)	3	46,XY,+15,-22	NO	0%
Paternal		46,XY,+15(×3),-22(×1)	5	46,XY,+15,-22	NO	0%
Paternal		46,XY,+15(×3),-22(×1)	8	46,XY,+15,-22	NO	0%
Paternal		46,XY,+15(×3),-22(×1)	20	46,XY,+15,-22	NO	0%
Paternal	2	45,XY,-20(×1)	3	45,XY,-20	NO	0%
Paternal		45,XY,-20(×1)	5	45,XY,-20	NO	0%
Paternal		45,XY,-20(×1)	8	NA [¶]	NA [¶]	NA [¶]
Paternal		45,XY,-20(×1)	20	45,XY,-20	NO	0%
Paternal	3	47,XX,+16(×3)	3	47,XX,+16	NO	0%
Paternal		47,XX,+16(×3)	5	47,XX,+16	NO	0%
Paternal		47,XX,+16(×3)	8	47,XX,+16	NO	0%
Paternal		47,XX,+16(×3)	20	47,XX,+16	NO	0%
Maternal	4	45,XX,-20(×1)	1	45,XX,-20(×1) [§]	NO	0%
Maternal		45,XX,-20(×1)	2	46,XX,-20(×1,mos,73%)	YES	20%
Maternal		45,XX,-20(×1)	3	46,XX,-20(×1,mos,71%)	YES	32%
Maternal	5	45,XX,-22(×1)	1	45,XX,-22(×1,mos,89%)	NO	0%
Maternal		45,XX,-22(×1)	2	46,XX,-22(×1,mos,70%)	YES	22%
Maternal		45,XX,-22(×1)	3	46,XX,-22(×1,mos,68%)	YES	34%
Maternal	6	45,XY,-22(×1)	8	46,XY,+X(×2,mos,66%),-Y(×0,mos,52%)	YES	59%

Maternal	45,XY,-22(×1)	12	46,XY,+X(×2,mos,45%,-Y(×0,mos,45%,-22(×1,mos,41%)	YES	60%
Maternal	45,XY,-22(×1)	15	46,XY,+Xp(p22.33→p22.2,~15Mb,×2),+Xp(p21.1→p11.21,~26Mb,×2),+Xq(×2,mos,70%,-Y(×0,mos,63%)	YES	>70%
Maternal	45,XY,-22(×1)	40	46,XY,+X(×2,mos,63%,-Y(×0,mos,62%)	YES	>70%

* The cut-off for qPCT is set as 10%.

[¶] Failed NGS.

[§] Over 10 biopsy TE cells mixed with single cumulus cell or failed addition of the single cumulus cell.

Isolation of sperm and cumulus cells

MALBAC-based WGA

Low-depth sequencing

CNV analysis

Preparation of parental and fetal gDNA

Mixture of gDNA in proportion

Dilution and MALBAC-WGA

Microarray genotyping

qPCT analysis

A**CNV analysis****qPCT analysis**

46,XY,+15(×3),-22(×1)

46,XY,+15(×3),-22(×1)

46,XY,+15(×3),-22(×1)

46,XY,+15(×3),-22(×1)

B**CNV analysis****qPCT analysis**

45,XX,-22(×1)

46,XX,-22(×1,mos,89%)

46,XX,-22(×1,mos,70%)

46,XX,-22(×1,mos,68%)

A

B

C

D

Frozen IVF PGT-A